Gene Techno Science : Signed alliance agreement with Eil for business development in regenerative medicine and healthcare area
January 31, 2020 at 07:58 am
Share
Eil is an affiliate of IMS group, one of the largest healthcare group, which drives a comprehensive spectrum of medical services, ranging from preventive medicine and urgent care to medical treatment, rehabilitation, nursing, and at-home support.
IMS group supports IDRM (Institute of Developmental and Regenerative Medicine through Tetsuya Nakamura Memorial Foundation in which Mr. Nakamura is a representative director. Eil is aggressively tackling with regenerative medicine by proceeding with basic research with academia and industry. Especially, regarding cord blood bank, Eil shows robust outcome and owns an advanced facility and equipment, for instance, having its storage facility authenticated by Association of American Blood Banks (AABB). Gene Techno Science (GTS) is culturing and banking and storing SHED (Stem cells from human exfoliated deciduous teeth) from milk teeth obtained from our partner dentists across Japan, and aggressively conducting research and development activities for realizing clinical application by collaborating with academia and industry. We are also partnering with Eil through our subsidiary, Advanced Cell Technology.
Both Eil and GTS agreed on accelerating and deepening business development by combining Eil's business infrastructure for regenerative medicine and our SHED, and then, made this agreement by concluding that it is best to establish more solid partnership. Based on this agreement we will continue to discuss about possible business development in regenerative medicine and healthcare area by combining both companies' business infrastructure, etc. for instance, a business development aiming at realizing clinical application of SHED and growth factor, etc. by utilizing Eil's technology, know-how, human resources, distribution network, etc.
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
KIDSWELL BIO CORPORATION 
